Increased Cortisol Cortisone Ratio in Acute Pulmonary Tuberculosis

Increased Cortisol Cortisone Ratio in Acute Pulmonary Tuberculosis ROBERT W. BAKER, BRIAN R. WALKER, RORY J. SHAW, JOHN W. HONOUR, DAVID S. JESSOP, ST...
Author: Earl Flowers
0 downloads 0 Views 175KB Size
Increased Cortisol Cortisone Ratio in Acute Pulmonary Tuberculosis ROBERT W. BAKER, BRIAN R. WALKER, RORY J. SHAW, JOHN W. HONOUR, DAVID S. JESSOP, STAFFORD L. LIGHTMAN, ALIMUDDIN ZUMLA, and GRAHAM A. W. ROOK Centre for Infectious Diseases and Department of Bacteriology, University College and Royal Free School of Medicine, London; Department of Respiratory Medicine, NHLI, Imperial College, London; Division of Molecular Pathology, University College London; Department of Medicine, University of Bristol, Bristol, United Kingdom; and Endocrinology Unit, University of Edinburgh, Edinburgh, Scotland

To evaluate a possible role for altered cortisol metabolism in mediating the immunoparesis associated with progressive tuberculosis (TB), we have studied the hypothalamic-pituitary-adrenal axis, and the activities of the 11␤-hydroxysteroid dehydrogenases (11HSDs) that interconvert active cortisol and inactive cortisone. In active pulmonary tuberculosis (PTB), the ratio of cortisol/cortisone metabolites in 24-h urine showed a shift towards active cortisol (ratio, 1.19 ⫾ 0.1, n ⫽ 16 versus 0. 89 ⫾ 0.05 in cured pulmonary tuberculosis (CTB), n ⫽ 13, p ⬍ 0. 01; and 0.78 ⫾ 0.04 healthy volunteers (HV), n ⫽ 11, p ⬍ 0.005). Conversion of cortisone (administered as 25 mg orally) to cortisol in peripheral plasma was higher in PTB (peak 1,157 ⫾ 55 nM, n ⫽ 14 versus 862 ⫾ 50 nM in CTB, n ⫽ 10, p ⬍ 0.005, and 882 ⫾ 73 nM in HV, n ⫽ 10; p ⬍ 0.005). Cortisol/cortisone ratio was increased in bronchoalveolar lavage fluid in PTB (7.73 ⫾ 1.48, mean ⫾ SE, n ⫽ 13) compared with HV (4.05 ⫾ 0.38, n ⫽ 11, p ⬍ 0.05) but was not different in plasma (PTB, 3.25 ⫾ 0.68; HV, 4.01 ⫾ 0.92). Responses of plasma cortisol to dexamethasone, CRH stimulation, and multidose ACTH stimulation were not different. These data suggest that in pulmonary tuberculosis, central control of glucocorticoid production is normal but that peripheral metabolism, in particular in the lung, is deviated in favor of the active metabolite cortisol. This offers a possible mechanism to explain the immunoparesis observed in progressive pulmonary tuberculosis.

Tuberculosis, a reemerging disease, is recognized to be associated with a degree of compromise of the immune system, particularly failing Th1 cytokine responses and overproduction of IL-10 and TGF-␤ (1–4). One mechanism by which this might be achieved is via the exposure of immune cells to abnormal relative local concentrations of glucocorticoids (5–7). To evaluate this possibility we investigated the hypothesis that within the tissues infected by M. tuberculosis there is a local imbalance in the ratio of cortisol to biologically inactive cortisone. There are complex relationships between glucocorticoids and defense against tuberculous infection. Administration of synthetic glucocorticoids induces reactivation of tuberculosis in humans (8, 9) and in animals (10). Conditions of war, stress, and deprivation lead to spontaneous reactivation of tuberculosis (11) and it may be that elevated concentrations of the principal endogenous glucocorticoid, cortisol, are responsible. Adrenal function in human tuberculosis has previously been investigated with variable and inconclusive results (12). In a previous study of 24-h urinary cortisol metabolites in patients with active pulmonary tuberculosis (13), we noted a marked

elevation in the ratio of metabolites of cortisol to those of its inactive derivative cortisone. The interconversion of cortisol and cortisone is catalyzed by 11␤-hydroxysteroid dehydrogenases (11-HSDs), which exist as at least two distinct enzymes. 11-HSD type 2 is a widely expressed high-affinity enzyme. It acts as an exclusive 11-dehydrogenase, notably in the distal nephron, where it converts cortisol to cortisone and thereby protects renal mineralocorticoid receptors from inappropriate activation by cortisol (14– 17). 11-HSD2 is also present in human lung (18) and in lymph nodes (19). In contrast, 11-HSD type 1 (20) is a low-affinity enzyme expressed in multiple tissues, including liver and lung (21–24). In most tissues, 11-HSD1 acts a reductase, converting cortisone to cortisol. In this study we have examined both central control of glucocorticosteroids and peripheral metabolism by assessing basal cortisol secretion, responses to stimulation and suppression of the hypothalamo-pituitary adrenal axis, net whole-body metabolism of cortisol by 11-HSDs, and specific metabolism of cortisol in the lung. These investigations were performed in patients with active tuberculosis, previous cured tuberculosis, acute nontuberculous pneumonia, and matched normal control subjects.

METHODS Patient Groups The study groups included 30 patients with active pulmonary tuberculosis confirmed by auramine staining of sputum or bronchoalveolar lavage fluid, and by subsequent culture; 14 patients with microbiologically proven previous pulmonary tuberculosis who completed treatment between 6 and 23 mo before the study; 23 healthy volunteers with no clinical evidence of tuberculosis and receiving no medication; and six patients with a diagnosis of acute pneumonia, based upon clinical presentation, chest radiograph revealing consolidation, and/or sputum culture. Demographic details for all groups are recorded in Table 1. All participants gave written informed consent for the studies, which were approved by the local ethical committees of St. Mary’s Hospital and University College Hospital, London. For all participants, exclusion criteria included: corticosteroid or androgen therapy by any route during the preceding 12 mo; abnormal thyroid or liver function tests; hypertension requiring medical therapy; diabetes mellitus; clinical depression during the preceding 12 mo; obesity (body mass index ⬎ 30 kg/m2); previous organ-specific autoimmune disease; positive HIV serology (all patients were tested for HIV infection). Not all participants underwent all investigations; numbers are given with results.

Protocol (Received in original form December 28, 1999 and in revised form February 14, 2000) Supported by The Wellcome Trust, The Neuroendocrinology Charitable Trust, and The Middlesex Hospital Special Trustees. Dr. Walker is a senior Research Fellow of the British Heart Foundation. Correspondence and requests for reprints should be addressed to Professor Rory Shaw, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK. Am J Respir Crit Care Med Vol 162. pp 1641–1647, 2000 Internet address: www.atsjournals.org

Strict adherence to protocol was maintained for all subjects to prevent effects caused by stress responses. The following measurements were made before any treatment: (1) 24-h urine collection for cortisol metabolites; (2) intravenous cannulation at 8:30 A.M. after overnight fast and withdrawal of blood after 30 min supine at 9:00 A.M. for serum cortisol, renin activity, aldosterone, and electrolytes; and (3) 4 hourly saliva collection (using Salivette; Sarstedt, Leicester, UK) for cortisol. All healthy volunteers and patients with active or cured tuberculo-

1642

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

VOL 162

2000

TABLE 1 DEMOGRAPHIC DETAILS OF PARTICIPANTS Subjects Undergoing Bronchoalveolar Lavage

Age, mean yr (range) Sex, female/total Ethnic origin (Afrocaribbean/Asian/Caucasian) Body mass index, kg/m2 Hospitalized during study Withdrawals during study

Healthy Volunteers

Acute Tuberculosis

Cured Tuberculosis

Acute Pneumonia

Healthy Volunteers

Acute Tuberculosis

30 (19–68) 6/13

39 (16–76) 8/17

48 (19–81) 6/14

30 (17–45) 1/6

30 (22–42) 2/11

37 (19–60) 5/13

4/4/5 23.02 ⫾ 0.46 0 3

4/4/9 20.9 ⫾ 0.5 11 5

2/2/10 20.1 ⫾ 0.5 0 4

0/1/5 Not available 5 0

4/1/6 23.4 ⫾ 0.64 0 0

3/2/6 20.8 ⫾ 0.84 9 0

sis were then treated with pyrazinamide (⬍ 50 kg body weight 1.5 g, ⬎ 50 kg body weight 2 g), pyridoxine (10 mg), ethambutol (25 mg/kg body weight) and isoniazid (300 mg). Administration was once daily by mouth for all drugs. Rifampicin, as an inducer of hepatic drug metabolizing enzymes that reduces the bioavailability of glucocorticoids, was omitted for the duration of the investigations. After 48 h, the following measurements were made. Day 1: 24-h urine collection for cortisol metabolites and four hourly saliva collection for cortisol. Day 2: corticotrophin-releasing hormone (CRH) test in which 100 ␮g ovine CRH (Ferring Pharmaceuticals Ltd. Feltham Middlesex UK) was injected at 9:00 A.M. and blood was withdrawn for 60 min from an intravenous cannula for cortisol and ACTH. Day 3: overnight threshold dose dexamethasone suppression test in which 250 ␮g dexamethasone was taken orally at 11:00 P.M., and subjects attended at 9:00 A.M. for cannulation and blood withdrawal for measurement of serum cortisol and dexamethasone. This was followed by oral administration of cortisone acetate (25 mg) and withdrawal of blood at intervals of 150 min for serum cortisol. Day 4: a second low dose suppression test performed as on Day 3 but with 2 mg dexamethasone. This was followed by sequential stimulation with boluses of ACTH1–24 (Synacthen; Ciba, Horsham, UK) 60 ng, 150 ng, and 250 ␮g at 90-min intervals and withdrawal of blood at intervals for serum cortisol over 240 min.

Control Patients with Pneumonia Six patients with nontuberculous pneumonia were studied during antibiotic treatment. Samples were collected for baseline urine measure-

ments as above. These patients were not given antituberculosis therapy, and did not participate in dynamic tests.

Bronchoalveolar Lavage Eleven patients with tuberculosis and 13 healthy volunteers provided specimens for bronchoalveolar lavage. The procedure was performed before any antituberculosis treatment was initiated. In both patients and healthy volunteers lavage was performed during an infusion of cortisol 4 ␮g/kg/min in order to ensure high substrate concentrations for 11-HSD activities and counteract any interindividual effects of stress. The infusion followed a 3-mg intravenous bolus of cortisol and was run for 240 min before the procedure in order to obtain a steadystate condition. The infusion continued during the lavage. Blood was sampled before the infusion was commenced, and immediately after the procedure. Both patients and healthy volunteers were sedated before a flexible bronchoscope was passed into either the diseased segment or the right middle lobe. Then 250 ml of normal saline were instilled in 50-ml aliquots with the end of the bronchoscope wedged in a subsegmental bronchus and fluid aspirated after minimal dwell time (25).

Assays Urine was analyzed for conjugated and unconjugated metabolites of cortisol by gas chromatography and mass spectrometry (GC/MS), as previously described (13). Serum and salivary cortisol and serum ACTH were measured by radioimmunoassays, as were plasma renin activity and aldosterone. Serum dexamethasone was measured by gas

TABLE 2 BIOCHEMICAL RESULTS FROM STUDIES EVALUATING HPA AXIS AND PERIPHERAL GLUCOCORTICOID METABOLISM* Acute Tuberculosis

Urinary tetrahydrocortisone, ␮g/d Urinary 5␤-tetrahydrocortisol (THF), ␮g/d Urinary 5␣-tetrahydrocortisol (alloTHF), ␮g/d Total urinary cortisol metabolite excretion, ␮g/d† THF/alloTHF‡ Serum dexamethasone (ng/ml) after dexamethasone 250 ␮g Serum cortisol (nmol/L) after dexamethasone 250 ␮g Serum dexamethasone after 2 mg, ng/ml Serum cortisol (nmol/L) after dexamethasone 2 mg Serum albumin g/L Plasma cortisol binding globulin, ␮g/ml

Cured Tuberculosis

Healthy Volunteers

Pneumonia

Before

During

Before

During

Before

During

During

1,309 ⫾ 153 1,088 ⫾ 138 437 ⫾ 71 4,530 ⫾ 537 2.94 ⫾ 0.4

1,830 ⫾ 268 1,597 ⫾ 240 775 ⫾ 190 6,459 ⫾ 857 2.82 ⫾ 0.5

1,209 ⫾ 278 715 ⫾ 170 326 ⫾ 72 3,720 ⫾ 881 2.28 ⫾ 0.3

1,292 ⫾ 299 738 ⫾ 228 516 ⫾ 107 4,563 ⫾ 1,144 1.63 ⫾ 0.23

1,668 ⫾ 178 744 ⫾ 92 561 ⫾ 78 4,779 ⫾ 564 1.54 ⫾ 0.22

1,655 ⫾ 270 813 ⫾ 136 673 ⫾ 210 5,006 ⫾ 871 1.67 ⫾ 0.23

1,583 ⫾ 264 888 ⫾ 197 458 ⫾ 80 4,182 ⫾ 732 1.93 ⫾ 0.25

40.1 ⫾ 0.9 22.77 ⫾ 1.83

2.2 ⫾ 0.4

2.3 ⫾ 0.3

271 ⫾ 63 8.5 ⫾ 1.9

174 ⫾ 40 9.9 ⫾ 1.6

47 ⫾ 9

41.6 ⫾ 0.8 20.84 ⫾ 4.93

48 ⫾ 6

3.1 ⫾ 0.79 139 ⫾ 44 7.0 ⫾ 1.1

40.4 ⫾ 0.6 19.97 ⫾ 2.32

38 ⫾ 4

* Values are mean ⫾ SEM. † Total urinary cortisol metabolites refers to all breakdown products of cortisol, i.e., tetrahydrocortisol (THF) ⫹ alloTHF ⫹ tetracortisol (THE) ⫹ cortols ⫹ cortolones. ‡ ANOVA before treatment between groups p ⬍ 0.05; patients with acute tuberculosis had a higher ratio than did healthy volunteers, p ⬍ 0.01. ANOVA during treatment between groups p ⬍ 0.05; patients with acute tuberculosis had a higher ratio than healthy volunteers (p ⬍ 0.01) or patients cured of tuberculosis (p ⬍ 0.01) or patients with pneumonia (p ⫽ 0.07, i.e., NS). Two-way ANOVA was used to examine potential confounding effects of sex. The observed differences between groups were independent of male/female composition of each group.

Baker, Walker, Shaw, et al.: Cortisol Metabolism in Pulmonary Tuberculosis chromatography and mass spectrometry. Cortisol binding globulin was measured by radioimmunoassay (Medgenix radioimmunoassay kit; Lifescreen, Watford, UK). Cortisol and cortisone were measured in bronchoalveolar lavage fluid by radioimmunoassay after extraction on a C18 SepPak (Waters Millipore, Watford, UK), elution with methanol, and separation by HPLC.

Data Interpretation Activity of the hypothalamo-pituitary adrenal axis was reflected in several indices. (1) Cortisol production rate, estimated from the sum of the daily excretion of the principal urinary metabolites of cortisol and cortisone (5␤-tetrahydrocortisol [THF], 5␣-tetrahydrocortisol [alloTHF], tetrahydrocortisone [THE], ␣- and ␤-cortols, and ␣- and ␤-cortolones); (2) diurnal variation of salivary cortisol; (3) stimulation of both ACTH and cortisol by CRH; (4) stimulation of cortisol by threshold doses of exogenous ACTH; and (5) suppression of plasma cortisol at two different circulating concentrations of dexamethasone. Metabolism of glucocorticoids was estimated by: (1) ratios of urinary metabolites of cortisol, from which 11-HSD activities are reflected in (THF ⫹ allo-THF)/THE ratio, and the balance of 5␣- and 5-␤ reductase activities are reflected in THF/allo-THF ratio; (2) the accumulation of cortisol in peripheral serum after oral administration of cortisone, which reflects predominant 11-reductase activity (26); and (3) the ratio of cortisol to cortisone in bronchoalveolar lavage fluid and plasma.

Statistical Analysis Variables were compared between groups, and across time-courses, by analysis of variance followed by least squares difference tests when appropriate, or by the Mann-Whitney U test. Relationships between

1643

continuous variables were compared by multiple regression analysis, in which qualitative variables were assigned values of 0 and 1 (27).

RESULTS The Hypothalamo-pituitary Adrenal Axis

Baseline and dynamic tests found no differences in the hypothalamic pituitary adrenal access between patients with acute tuberculosis and the control groups. Twenty-four-hour urine. In patients with active pulmonary tuberculosis, compared with other groups, there was no change in total cortisol metabolite excretion rate (Table 2). There was no significant change in cortisol production rate after 3 d of treatment. The diurnal rhythm of cortisol concentrations. Salivary cortisol concentrations were higher at 8:00 P.M. in samples from the patients with active tuberculosis than in those from other groups (Figure 1a and 1b). This abnormality was found in the samples taken before initiation of antituberculosis therapy, but was not significant after 3 d of treatment. This observation might have been linked to stress of hospitalization since only the patients with active tuberculosis were admitted. Responsiveness of the adrenal to ACTH. After suppression of endogenous cortisol with a 2-mg dose of dexamethasone, the adrenals of patients with acute tuberculosis responded normally to the physiological challenges (60 ng and 150 ng) and also to the supraphysiological challenge (250 ␮g) with ACTH (Figure 2). Response of the pituitary to CRH. Plasma cortisol was not suppressed by dexamethasone before this test was performed. There were no significant differences between the groups in the increases in cortisol or ACTH that were observed after CRH (Figures 3a and 3b). Suppression by dexamethasone. Suppression of 9:00 A.M. plasma cortisol levels after 250 ␮g dexamethasone at 11:00 P.M. the previous night was similar in all groups (Table 2). Similarly, suppression of 9.00 A.M. cortisol levels to less than 50 nmol/L was achieved in all subjects after 2 mg dexamethasone (Table 2). The concentrations of plasma dexamethasone achieved at each dose did not differ between groups (Table 2). Cortisol Metabolism

Both the 24-h urine analysis and study of conversion of an oral cortisone load identified a deviation of peripheral metabolism of glucocorticoids in favor of the active metabolite cortisol.

Figure 1. Diurnal variation of salivary cortisol, mean ⫾ SEM. (a) Before antituberculosis therapy: patients with tuberculosis (n ⫽ 14) (closed circles); patients cured of tuberculosis (n ⫽ 13) (open triangles); healthy volunteers (n ⫽ 11) (open circles). (b) During antituberculosis therapy: patients with tuberculosis (n ⫽ 12) (closed circles); patients cured of tuberculosis (n ⫽ 11) (open triangles); healthy volunteers (n ⫽ 10) (open circles). Asterisk indicates significantly elevated value in patients with tuberculosis. ANOVA before therapy between groups p ⬍ 0.05, significant between acute tuberculosis and both other groups to p ⬍ 0.05. ANOVA during therapy not significant.

Figure 2. Serum cortisol responses, mean ⫾ SEM, to sequential ACTH stimulation tests after dexamethasone 2 mg. Patients with tuberculosis (n ⫽ 11) (closed circles); patients cured of tuberculosis (n ⫽ 11) (open triangles); healthy volunteers (n ⫽ 11) (open circles). No significant differences between groups.

1644

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Figure 3. (a) Cortisol and (b) ACTH responses to CRH administered at time 0, mean ⫾ SEM. Patients with tuberculosis (n ⫽ 12) (closed circles); patients cured of tuberculosis, (n ⫽ 11) (open triangles); healthy volunteers (n ⫽ 12) (open circles). No significant differences between groups.

Twenty-four-hour urine collections. In patients with active pulmonary tuberculosis the ratio of urinary metabolites of cortisol relative to metabolites of cortisone (Figure 4) was increased. Thus, the urinary cortisol: cortisone metabolite ratio in patients with active pulmonary tuberculosis (n ⫽ 16) of 1.19 (⫾ 0.1) was greater than that in healthy volunteers (n ⫽ 11) of 0.78 ⫾ 0.04 (p ⬍ ⫺0.005) or in patients with previously cured pulmonary tuberculosis (n ⫽ 13) who had values of 0.89 ⫾ 0.05 (p ⬍ 0.01). This remained significant during 3 d of treatment in hospital. Thus, the results of measurements after 48 h of therapy (excluding rifampicin) revealed in those with acute pulmonary tuberculosis (n ⫽ 12), a urinary cortisol: cortisone metabolite ratio of 1.37 ⫾ 0.18, which was greater than in the healthy volunteers whose ratio was 0.85 ⫾ 0.07 (n ⫽ 10) p ⬍ 0.005, those with cured tuberculosis with a ratio of 1.03 ⫾ 0.18 (n ⫽ 10) p ⬍ 0.01, and acute pneumonia with a ratio of 0.9 ⫾ 0.16 (n ⫽ 6) p ⬍ 0.05. On treatment ANOVA between groups was p ⬍ 0.05. Those patients with acute nontuberculous pneumonia, who were receiving various antibiotic regimens at the time of sampling, showed a range in the ratio of cortisol to cor-

VOL 162

2000

tisone metabolites, but with no differences from other control groups. In multiple regression analyses, sex, ethnic origin, body mass index, and age did not account for differences in cortisol/cortisone metabolite ratios between groups. There was also an increase in the ratio of 5␤- to 5␣-tetrahydrocortisol in patients with active pulmonary tuberculosis (Table 2). Thus, the urinary 5␤- to 5␣-tetrahydrocortisol ratio in patients with active pulmonary tuberculosis (n ⫽ 16) of 2.94 ⫾ 0.4 was greater than that in healthy volunteers (n ⫽ 11), 1.54 ⫾ 0.22 (p ⬍ 0.05). Patients with previously cured pulmonary tuberculosis (n ⫽ 13) had values of 2.28 ⫾ 0.3 (p ⫽ NS). This remained significant during 3 d of treatment in hospital. Thus, the results of measurements after 48 h of therapy (excluding rifampicin) revealed in those with acute pulmonary tuberculosis (n ⫽ 12), a urinary 5␤- to 5␣-tetrahydrocortisol of 2.82 ⫾ 0.5, which was greater than in the healthy volunteers whose ratio was 1.67 ⫾ 0.23 (n ⫽ 10) p ⬍ 0.01, those with cured tuberculosis with a ratio of 1.63 ⫾ 0.23 (n ⫽ 10) p ⬍ 0.01, and those with acute pneumonia with a ratio of 1.93 ⫾ 0.25 (n ⫽ 6) p ⫽ 0.07. Conversion of cortisone to cortisol after an oral cortisone load. After suppression of plasma cortisol with 250 ␮g dexamethasone, and administration of 25 mg oral cortisone, peak plasma cortisol concentrations were higher in patients with active tuberculosis relative to other groups (Figure 5). Patients with tuberculosis (n ⫽ 14) achieved a significantly higher peak of plasma cortisol (1,157 ⫾ 55 nmol/L) than healthy volunteers (n ⫽ 10) whose peak was 882 ⫾ 73 nmol/L, p ⬍ 0.005, or patients cured of tuberculosis (n ⫽ 10) who had a maximum of 862 ⫾ 50 nmol/L, p ⬍ 0.001. ANOVA between groups was p ⬍ 0.005. There were no differences in corticosteroid binding globulin (Table 2) or baseline plasma cortisol (Figure 5) between groups. Pulmonary Metabolism of Glucocorticoids

Cortisol/cortisone ratios in bronchoalveolar lavage fluid were higher in patients with tuberculosis when compared with other groups (Table 3). Patients with acute tuberculosis (n ⫽ 13) achieved a higher cortisol/cortisone ratio of 7.73 ⫾ 1.48 compared with healthy volunteers (n ⫽ 11) whose ratio was 4.05 ⫾ 0.38 (p ⬍ 0.05). By contrast plasma cortisol and cortisone concentrations were not different in patients with tuberculosis compared with those in healthy control subjects at baseline or during cortisol infusion. Cortisol/cortisone ratios in plasma were rather variable, but not different between groups. Cortisol/cortisone ratios in lavage fluid did not correlate with ratios or absolute levels of cortisol in plasma (BAL ratio versus plasma

Figure 4. Ratio of urinary metabolites of cortisol (THF ⫹ alloTHF) to metabolites of cortisone (THE) in groups before (top panel) and during (bottom panel) treatment, mean ⫾ SEM. “During treatment” refers to antituberculosis chemotherapy for 48 to 72 h in all groups apart from those with acute pneumonia, who were treated with various antibiotics and for varying durations. Patients with tuberculosis (TB) had significantly elevated ratios compared with healthy volunteers, cured patients, or patients with pneumonia. ANOVA between groups before treatment p ⬍ 0.005, significant between acute tuberculosis and both cured TB and healthy volunteers to p ⬍ 0.01. ANOVA between groups during treatment p ⬍ 0.02. The differences between individual ratios during treatment were significant to the following p values: Acute TB:HV, p ⬍ 0.005; Acute TB:Cured TB, p ⬍ 0.01; Acute TB:pneumonia, p ⬍ 0.05. Discrepancies in sample numbers compared with those in Table 1 relate to incomplete 24-h urine collections.

1645

Baker, Walker, Shaw, et al.: Cortisol Metabolism in Pulmonary Tuberculosis

Figure 5. Accumulation of cortisol in serum after oral administration of cortisone acetate 25 mg, mean ⫾ SEM. Subjects had received dexamethasone 250 ␮g at 11:00 P.M. the previous night. The cortisone tablet was administered at 9:00 A.M. Patients with tuberculosis (n ⫽ 14) (closed circles); patients cured of tuberculosis (n ⫽ 10) (open triangles); healthy volunteers (n ⫽ 10) (open circles). Patients with tuberculosis achieved a significantly higher peak of plasma cortisol (1,157 ⫾ 55 nmol/L) than healthy volunteers (882 ⫾ 73 nmol/L, p ⬍ 0.005) or patients cured of tuberculosis (862 ⫾ 50 nmol/L, p ⬍ 0.001). ANOVA between groups p ⬍ 0.005.

ratio R ⫽ ⫺0.01, p ⫽ 0.95; BAL ratio versus plasma cortisol concentration R ⫽ ⫺0.125, p ⫽ 0.57).

DISCUSSION This detailed and comprehensive investigation of cortisol metabolism examined patients with active pulmonary tuberculosis, patients with cured tuberculosis, patients with nontuberculous lung infection, and healthy control subjects. We found central regulation of the hypothalamo-pituitary-adrenal axis to be remarkably normal in active tuberculosis, but we confirmed our previous observation (13) that peripheral metabolism of cortisol is perturbed. We have further demonstrated that this disturbance occurs during active tuberculous infection only. The normal response in patients with previously cured tuberculosis argues against the possibility that the abnormalities were intrinsic to subjects predisposed to tuberculosis. The study found evidence that the change in peripheral steroid metabolism was associated with an increased ratio of active glucocorticoid metabolite cortisol in the lung. Previous studies of patients with tuberculosis have included only limited analyses of regulation of cortisol secretion. These studies showed variable loss of diurnal rhythm of plasma cortisol associated with a highly variable impaired response to a phar-

macologic dose of exogenous ACTH. The confounding effects of hospitalization and drug therapy were not always accounted for. In the present study, we were unable, for ethical reasons, to complete all of our investigations before starting antituberculosis therapy, but we did collect baseline saliva, blood, and urine specimens and repeated these tests 48 h after starting therapy. The baseline tests showed that total cortisol metabolite excretion, an index of cortisol production rate, did not differ in patients with active tuberculosis. The higher salivary cortisol in the evening in these patients may be attributable to the effect of acute hospitalization, particularly since it was less striking 3 d later, when the patients had started therapy and acclimatized to the hospital environment. It was not possible for subjects in the control groups to be admitted to hospital. After these assessments, we administered the same drugs (which excluded the liver enzyme inducer rifampicin) to patients and to the two control groups, a healthy group and a group who had previously been cured of tuberculosis. Urinary cortisol metabolite excretion did not change after drug therapy in any group, indicating that further dynamic tests of cortisol secretion and metabolism can be interpreted with reference to the untreated state. Dynamic tests of the hypothalamo-pituitary-adrenal axis performed during antituberculosis treatment showed no difference between patients with active tuberculosis and any of the control groups in cortisol responses to suppression with dexamethasone or stimulation with CRH or ACTH. Importantly, both the dexamethasone and ACTH responses were assessed using very low threshold doses as well as pharmacologic doses. The lack of difference in response to ACTH is in contrast to previous reports (12). It is possible that the different results after ACTH stimulation reflect differences in the prevalence of adrenocortical tuberculous infection in different groups of patients. Although hypothalamic pituitary adrenal axis function appeared normal, the study did detect changes in peripheral metabolism of corticosteroids and suggests altered 11-HSD function resulting in a relative increase in cortisol. This study does not address whether the shift in the equilibrium point of the enzymes that convert cortisol and cortisone occurs in all tissues where it is expressed, or only in some sites. Although the generation of cortisol in the peripheral circulation after oral cortisone administration is thought to reflect predominately first-pass metabolism in the liver (28), it may also be influenced by the cortisol/cortisone equilibrium in other sites. Given its potential relevance to pulmonary tuberculous infection, we addressed specifically whether the altered cortisol/ cortisone equilibrium affected intrapulmonary glucocorticoid concentrations. There is substantial expression of both 11HSD1 and 11-HSD2 in the lung (18, 22, 24, 29, 30), and the

TABLE 3 BIOCHEMICAL RESULTS FROM BRONCHOALVEOLAR LAVAGE STUDY

Plasma cortisol before lavage, nmol/L Plasma cortisone before lavage, nmol/L Plasma cortisol during lavage, nmol/L Plasma cortisone during lavage, nmol/L Plasma cortisol/cortisone ratio during lavage Lavage fluid cortisol, nmol/L Lavage fluid cortisone, nmol/L BAL cortisol: cortisone ratio * Values are mean ⫾ SEM. † Mann-Whitney U test.

Acute Tuberculosis*

Healthy Volunteers*

p Value†

542 ⫾ 66 167 ⫾ 31 1,855 ⫾ 176 267 ⫾ 65 27.3 ⫾ 14.7 20.8 ⫾ 4.5 3.65 ⫾ 1.0 7.73 ⫾ 1.48

618 ⫾ 117 272 ⫾ 100 1,814 ⫾ 138 322 ⫾ 64 17.4 ⫾ 8.2 14.43 ⫾ 2.6 4.16 ⫾ 0.9 4.05 ⫾ 0.38

0.64 0.64 0.21 0.66 0.12 0.34 0.43 0.039

1646

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

enzymes are known to be active with cortisol and cortisone having previously been quantified in BAL by gas chromatography negative ion chemical ionization mass spectrometry (22). In this single previous study by Hubbard and colleagues (22) BAL cortisone was measured in healthy volunteers as 1.05 nmol/L and cortisol as 0.42 nmol/L. In the present study we have measured cortisol and cortisone in bronchoalveolar lavage fluid using HPLC and RIA. We attribute the discrepancy in the absolute concentrations obtained in normal subjects between the present study (Table 3) and that of Hubbard and colleagues (22) to the supraphysiologic dosage of cortisol, which we infused for the reasons outlined above in all subjects. Crucially, despite there being no difference in circulating plasma cortisol concentrations or plasma cortisol/cortisone ratios between patients with acute tuberculosis and healthy volunteers, the patients with active pulmonary tuberculosis had higher cortisol/cortisone ratios in bronchoalveolar lavage fluid. With the methodologies available it was not possible to distinguish the influence of pulmonary 11␤-HSD2 and 11␤HSD1 activities on the cortisol: cortisone ratio in the lung. Although the data from this study do not address the mechanism for altered cortisol metabolism in tuberculosis, possibilities include the recognized regulation of 11-HSD type 1 by the cytokines IL-1␤ and TNF-␣ (29). One or both of these cytokines is present in increased concentrations in bronchoalveolar lavage fluid and pleural effusions in human (31) and in murine (32) tuberculosis. Another physiologically plausible explanation would be decreased expression of 11-HSD type 2 (33). This study has thus provided at least a theoretical mechanism to link the release of proinflammatory cytokines IL-1␤ and TNF in tuberculosis via modulation of 11 HSD type 1 and a relative increase in tissue cortisol with a local impairment of the immune response to tuberculosis. Increased local conversion of cortisone to cortisol could explain the increased production of TGF-␤ (7) and IL-10 (5, 6) in human tuberculosis (1), and impaired macrophage function (34). Whether or not the shift in cortisol metabolism in favor of the active glucocorticoid is a primary or secondary phenomenon in reactivated pulmonary tuberculosis, this observation may provide a link to the recognized increase in susceptibility to tuberculosis reactivation during stress. Therapeutic opportunities may also arise, since manipulation of corticosteroids such as corticosterone and androstenediol have been shown to affect survival curves in a mouse model of tuberculosis (35). The interactions between the immune system and the factors controlling glucocorticoid metabolism therefore offer a novel therapeutic approach in tuberculosis. Acknowledgment: The writers greatly appreciate the technical assistance provided by Dr. Ruth Andrew, Mrs. Jill Smith, and Mrs. Elvira Conway. The assistance of the staff of the Chest & Allergy Clinic and the Endoscopy Unit of St Mary’s Hospital, Paddington, was also invaluable.

References 1. Ellner JJ. Regulation of the human immune response during tuberculosis. J Lab Clin Med 1997;130:469–475. 2. Murray PJ, Wang L, Onufryk C, Tepper RI, Young RA. T-cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. J Immunol 1997;158:315–321. 3. Vanham G, Toossi Z, Hirsch CS, Wallis RS, Schwander SK, Rich EA, Ellner JJ. Examining a paradox in the pathogenesis of human pulmonary tuberculosis: immune activation and suppression/anergy. Tuber Lung Dis 1997;78:145–158. 4. Toossi Z., Ellner JJ. The role of TGF beta in the pathogenesis of human tuberculosis. Clin Immunol Immunopathol 1998;87:107–114. 5. Visser J, van Boxel A, Dezaire A, Methorst D, Brunt T, de Kloet E, Nagelkerken L. Differential regulation of interleukin-10 (IL-10) and IL-12 by glucocorticoids in vitro. Blood 1998;91:4255–4264.

VOL 162

2000

6. Vieira PL, Kalinski P, Wierenga EA, Kapsenberg ML, de Jong E. Glucocorticoids inhibit bioactive IL-12p70 production by in vitro generated human dendritic cells without affecting their T cell stimulatory potential. J Immunol 1998;161:5245–5251. 7. Batuman OA, Ferrero A, Cupp C, Jimenez SA, Khalili K. Differential regulation of transforming growth factor beta-1 gene expression by glucocorticoids in human T and glial cells. J Immunol 1995;155:4397– 4405. 8. Haanaes OC, Bergmann A. Tuberculosis emerging in patients treated with corticosteroids. Eur J Respir Dis 1983;64:294–297. 9. Sahn SA, Lakshminarayan S. Tuberculosis after corticosteroid therapy. Br J Dis Chest 1976;70:195–205. 10. Brown DH, Miles BA, Zwilling BS. Growth of Mycobacterium tuberculosis in BCG-resistant and -susceptible mice: establishment of latency and reactivation. Infect Immun 1995;63:2243–2247. 11. Barr RG, Menzies R. The effect of war on tuberculosis: results of a tuberculin survey among displaced persons in El Salvador and a review of the literature. Tuber Lung Dis 1994;75:251–259. 12. Barnes DJ, Naraqi S, Temu P, Turtle JR. Adrenal function in patients with active tuberculosis. Thorax 1989;44:422–424. 13. Rook GAW, Honour J, Kon OM, Wilkinson RJ, Davidson R, Shaw RJ. Urinary steroid metabolites in tuberculosis; a new clue to pathogenesis. Q J Med 1996;89:387–394. 14. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 1994;105:R11–R17. 15. Edwards CRW, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase—tissue specific protector of the mineralocorticoid receptor. Lancet 1988;8618:986–989. 16. Funder JW, Pearce PT, Smith R, Smith AI. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242:583–585. 17. Kotelevtsev YV, Brown RW, Fleming S, Edwards CRW, Seckl JR, Mullins JJ. Hypertension in mice caused lacking 11b-hydroxysteroid dehydrogenase type 2. J Clin Invest 1999;103:683–688. 18. Suzuki T, Sasano H, Suzuki S, Hirasawa G, Takeyama J, Muramatsu Y, Date F, Nagura H, Krozowski ZS. 11 Beta-hydroxysteroid dehydrogenase type 2 in human lung: possible regulator of mineralocorticoid action. J Clin Endocrinol Metab 1998;83:4022–4025. 19. Hennebold JD, Ryu SY, Mu HH, Galbraith A, Daynes RA. 11 beta-hydroxysteroid dehydrogenase modulation of glucocorticoid activities in lymphoid organs. Am J Physiol 1996;270(6, Pt 2):R1296–R1306. 20. Agarwal AK, Monder C, Eckstein B, White PC. Cloning and expression of rat cDNA encoding corticosteroid 11 beta-dehydrogenase. J Biol Chem 1989;264:18939–18943. 21. Berliner DL, Dougherty TF. Hepatic and extrahepatic regulation of corticosteroids. Pharmacol Rev 1961;13:329–359. 22. Hubbard WC, Bickel C, Schleimer RP. Simultaneous quantitation of endogenous levels of cortisone and cortisol in human nasal and bronchoalveolar lavage fluids and plasma via gas chromatography-negative ion chemical ionization mass spectrometry. Anal Biochem 1994;221: 109–117. 23. Schleimer RP. Potential regulation of inflammation in the lung by local metabolism of hydrocortisone. Am J Respir Cell Mol Biol 1991;4:166– 173. 24. Rajan V, Chapman KE, Lyons V, Jamieson P, Mullins JJ, Edwards CRW, Seckl JR. Cloning, sequencing and tissue-distribution of mouse 11 beta-hydroxysteroid dehydrogenase-1 cDNA. J Steroid Biochem Mol Biol 1995;52:141–147. 25. Robinson DS, Ying S, Taylor IK, Wangoo A, Mitchell DM, Kay AB, Hamid Q, Shaw RJ. Evidence for a Th1-like bronchoalveolar T-cell subset and predominance of interferon-gamma gene activation in pulmonary tuberculosis. Am J Respir Crit Care Med 1994;149(4, Pt 1):989– 993. 26. Walker BR, Edwards CRW. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am. 1994;23:359–377. 27. Armitage P, Berry G. Statistical methods in medical research. Oxford: Blackwell; 1994. 28. Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CRW. Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol 1992;37:483–492. 29. Escher G, Galli I, Vishwanath BS, Frey BM, Frey FJ. Tumor necrosis factor alpha and interleukin-1 beta enhance the cortisone/cortisol shuttle. J Exp Med 1997;186:189–198.

Baker, Walker, Shaw, et al.: Cortisol Metabolism in Pulmonary Tuberculosis 30. Escher G, Frey FJ, Frey BM. 11 beta-hydroxysteroid dehydrogenase accounts for low prednisolone/prednisone ratios in the kidney. Endocrinology 1994;135:101–106. 31. Law K, Weiden M, Harkin T, Tchou Wong K, Chi C, Rom WN. Increased release of interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha by bronchoalveolar cells lavaged from involved sites in pulmonary tuberculosis. Am J Respir Crit Care Med 1996;153:799–804. 32. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ. 11 beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997;94:14924–14929.

1647

33. Tetsuka M, Thomas FJ, Thomas MJ, Anderson RA, Mason JL, Hillier SG. Differential expression of messenger ribonucleic acids encoding 11 beta- hydroxysteroid dehydrogenase types 1 and 2 in human granulosa cells. J Clin Endocrinol Metab 1997;82:2006–2009. 34. Brown DH, Sheridan J, Pearl D, Zwilling BS. Regulation of mycobacterial growth by the hypothalamus-pituitary-adrenal axis: differential responses of Mycobacterium bovis BCG-resistant and -susceptible mice. Infect Immun 1993;61:4793–4800. 35. Hernandez-Pando R, de la Luz Streber M, Orozco H, Arriaga K, Pavon L, Marti O, Lightman SL, Rook GAW. Emergent immunoregulatory properties of combined glucocorticoid and anti-glucocorticoid steroids in a model of tuberculosis. Q J Med 1998;91:755–766.

Suggest Documents